Clinical Trial Update: Controlling Hyperactive Immunity With Long-lived Lymphocytes [Phase 1, Phase 2]

View source ↗

Summary

Quell Therapeutics is running Phase 1/2 trials to control hyperactive immunity with long-lived lymphocytes, enrolling participants with diffuse cutaneous system…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis
• Rheumatoid Arthritis
• Systemic Sclerosis

Snippet

Sponsor: Quell Therapeutics Limited | Conditions: Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA) | Phase 1, Phase 2 | Status: RECRUITING